Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP decreased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 49.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,742 shares of the company's stock after selling 5,594 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in Protagonist Therapeutics were worth $222,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PTGX. RTW Investments LP grew its holdings in shares of Protagonist Therapeutics by 2.6% during the third quarter. RTW Investments LP now owns 5,426,112 shares of the company's stock worth $244,175,000 after purchasing an additional 139,708 shares during the last quarter. State Street Corp boosted its position in shares of Protagonist Therapeutics by 52.9% in the 3rd quarter. State Street Corp now owns 3,183,542 shares of the company's stock valued at $143,259,000 after purchasing an additional 1,101,218 shares during the period. Pacer Advisors Inc. boosted its position in shares of Protagonist Therapeutics by 8.2% in the 4th quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock valued at $72,432,000 after purchasing an additional 142,376 shares during the period. Geode Capital Management LLC grew its stake in Protagonist Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,374,697 shares of the company's stock worth $61,873,000 after buying an additional 3,528 shares during the last quarter. Finally, American Century Companies Inc. increased its position in Protagonist Therapeutics by 61.5% during the fourth quarter. American Century Companies Inc. now owns 928,286 shares of the company's stock worth $35,832,000 after buying an additional 353,511 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Protagonist Therapeutics Trading Down 1.1 %

Shares of PTGX traded down $0.56 during mid-day trading on Friday, hitting $48.88. The company's stock had a trading volume of 664,503 shares, compared to its average volume of 796,889. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $60.60. The firm has a market capitalization of $3.00 billion, a P/E ratio of 18.38 and a beta of 2.34. The firm has a 50-day simple moving average of $42.54 and a 200 day simple moving average of $42.90.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. As a group, sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Asif Ali sold 24,903 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the completion of the transaction, the chief financial officer now owns 62,821 shares in the company, valued at $3,689,477.33. This trade represents a 28.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total value of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares of the company's stock, valued at $4,676,140.08. This trade represents a 26.67 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,776 shares of company stock valued at $3,585,010. Corporate insiders own 5.40% of the company's stock.

Wall Street Analyst Weigh In

PTGX has been the topic of a number of research reports. The Goldman Sachs Group lowered their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. Wedbush reiterated an "outperform" rating and set a $70.00 price target on shares of Protagonist Therapeutics in a research note on Friday. BTIG Research set a $73.00 price objective on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. JMP Securities reiterated a "market outperform" rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Finally, StockNews.com cut Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Protagonist Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $62.56.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.